SG/CALL/BRISTOL-MYERS SQUIBB/80/0.1/20.12.24 | Delayed Deutsche Boerse AG 05:09:08 2024-05-22 EDT | ||
| 0.001 EUR | 0.00% |
|
| 3 months | -90.91% | ||
| 6 months | -94.12% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-05-22 | 0.001 | 0.00% |
| 24-05-21 | 0.001 | 0.00% |
| 24-05-20 | 0.001 | 0.00% |
| 24-05-17 | 0.001 | 0.00% |
| 24-05-16 | 0.001 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update May 22, 2024 at 05:09 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SV455A |
| ISIN | DE000SV455A0 |
| Date issued | 2023-05-09 |
| Strike | 80 $ |
| Maturity | 2024-12-20 (213 Days) |
| Parity | 10 : 1 |
| Emission price | 0.38 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.39 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.019 € |
| Spread % | 95.00% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
42.27
USD
Average target price
53.19
USD
Spread / Average Target
+25.84%
- Stock Market
- Warrants
- Warrant